CEL-SCI Corporation (CEL-SCI) - Form 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended September 30, 2009.
Company Profile: CEL-SCI is a biopharmaceutical company focused on developing immunotherapies and vaccines. It is classified as a smaller reporting company.
Core Business:
- Multikine: Lead product, a cancer immunotherapy (Immune SIMULATOR) in development for head and neck cancer. FDA cleared for a global Phase III trial expected to commence in summer 2010.
- Manufacturing Services: Offers "cold fill" manufacturing services for temperature-sensitive biologics from a dedicated facility in Baltimore, MD.
- LEAPS Technology: Platform for T-cell modulation. Includes LEAPS-H1N1 (swine flu treatment) and CEL-2000 (rheumatoid arthritis vaccine), both in early clinical/pre-clinical stages.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 |
|---|---|---|
| Revenue | $80,093 | $5,065 |
| Net Loss | $(40,910,030) | $(7,703,415) |
| Net Loss Per Share (Basic/Diluted) | $(0.31) | $(0.07) |
| Research & Development Expenses | $6,011,750 | $4,101,563 |
| General & Administrative Expenses | $5,671,595 | $5,200,735 |
| Cash and Cash Equivalents (End of Period) | $33,567,516 | $711,258 |
| Total Assets | $46,027,598 | $14,683,672 |
| Total Liabilities | $37,186,954 | $3,847,637 |
| Working Capital | $(1,580,623) | $(2,492,555) |
Note: The significant increase in cash and liabilities in 2009 is primarily due to equity financings and the accounting treatment of warrants as derivative liabilities.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased by approximately $33.2 million (338%) compared to 2008. This was driven largely by a $28.5 million loss on derivative instruments due to changes in the fair value of warrants and convertible notes, rather than operational costs.
- Financing Activity: The company raised over $39 million in gross proceeds through equity financings and warrant conversions during fiscal 2009, significantly improving liquidity from $0.7 million in cash (2008) to $33.6 million (2009).
- Derivative Liabilities: Total derivative liabilities surged from $3.0 million in 2008 to $35.1 million in 2009, reflecting the fair value of warrants issued in connection with recent financings.
- R&D Spend: R&D expenses increased by $1.9 million (47%) to support preparation for the Multikine Phase III clinical trial.
Outlook, Risks, and Contingencies
Guidance and Outlook:
- Phase III Trial: CEL-SCI expects to commence the pivotal Phase III clinical trial for Multikine in the summer of 2010. The estimated cost is approximately $20 million (excluding partner contributions).
- Capital Needs: The company anticipates incurring substantial losses for the foreseeable future and will require additional capital to fund operations and clinical trials.
- Manufacturing: The new manufacturing facility is validated and ready for Phase III production and potential commercial sales.
Key Risks and Contingencies:
- Litigation: Iroquois Master Fund Ltd. filed a lawsuit in October 2009 seeking $120 million in damages and additional shares/warrants, alleging the conversion price of Series K notes should be $0.20 instead of $0.40. CEL-SCI intends to defend the suit.
- Regulatory Approval: No products are currently approved for sale. Commercialization depends on successful Phase III trials and FDA/foreign regulatory approvals, which are uncertain and time-consuming.
- Dilution: Significant dilution is expected from outstanding options, warrants, and potential future equity issuances to fund operations.
- Lease Obligations: The company has a 20-year lease on its manufacturing facility with annual base rent of approximately $1.62 million, escalating 3% annually.
Investor Verification Checklist
- Cash Runway: Verify if the $33.6 million cash balance is sufficient to fund the $20 million Phase III trial and ongoing operations without immediate additional dilution.
- Derivative Liability Volatility: Monitor the fair value of derivative liabilities, as fluctuations in stock price will directly impact reported net loss.
- Litigation Status: Track the progress of the Iroquois Master Fund lawsuit, as an adverse ruling could result in significant share issuance and financial liability.
- Phase III Timeline: Confirm the start date of the Multikine Phase III trial (targeted summer 2010) and enrollment progress.
- Partner Funding: Verify the extent of funding contributions from partners (Orient Europharma, Teva, Byron Biopharma) toward clinical trial costs.